Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20190210042676N27
IRCT20190210042676N27
Recruiting
Phase 2

Evaluation of safety and clinical efficacy of Firooz brand name fissure cream containing lanolin in improving the pain and severity of fissure lesions in lactating women

Firooz Health Group Company0 sites20 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsFissure of nipple.Fissure and fistula of nippleN64.0

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Fissure of nipple.
Sponsor
Firooz Health Group Company
Enrollment
20
Status
Recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Firooz Health Group Company

Eligibility Criteria

Inclusion Criteria

  • •Lactating women aged 18 to 45 with term babies (weighing 2500 to 4000 grams)
  • •General health
  • •Signing the consent form for participation in the study
  • •Breast pain from severity 1 to 3

Exclusion Criteria

  • •People with puerperal fever
  • •A newborn suffering from jaw and mouth abnormalities such as short frenulum or oral infections
  • •Mothers suffering from diabetes
  • •Use of any local treatment for fissure three days before the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 3
Comparative study of the efficacy and safety of Formoterol
CTRI/2017/03/008277Rus Biopharm LLC136
Completed
Not Applicable
Validation study of the efficacy and safety of first precutting for Oral protrusion-Large, which is difficult to biliary duct cannulation.Cases requiring ERCP
JPRN-UMIN000042805Kitasato University School of Medicine38
Completed
Phase 2
Evaluation of safety and protective efficacy of fulminant hepatitis to abatacept treatment of patients with HBV-related severe hepatitis.-Pilot StudyHBV-related acute severe hepatitis
JPRN-UMIN000025725Hiroshima university hospital10
Active, not recruiting
Phase 1
Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder.
EUCTR2006-003658-47-FRPierre Fabre Médicament - IRPF180
Completed
Phase 3
Evaluation of Efficacy and Safety of Combination of Atorvastatin and Hydroxychloroquine with Atorvastatin alone in Patients with DyslipidemiaHealth Condition 1: null- primary dyslipidemia
CTRI/2010/091/006138Ipca Laboratories Ltd Mumbai328